Loading organizations...
§ Private Profile · New York City, NY, USA
AI dementia care navigation platform delivers comprehensive services for Medicare patients and providers, focused on CMS GUIDE Model.
Craniometrix has raised $7.5M across 2 funding rounds.
Key people at Craniometrix.
Craniometrix was founded in 2021 by Nikhil Patel (Founder).
Craniometrix has raised $7.5M in total across 2 funding rounds.
Based in New York, New York, Craniometrix develops an artificial intelligence platform that provides comprehensive dementia care navigation services and continuous caregiver support. The company utilizes the MIND at Home clinical model developed by Johns Hopkins Medicine to help healthcare providers participate in the federal Medicare GUIDE program. The platform serves specialized neurology practices such as Arizona Neurology Associates and Lone Star Neurology by coordinating respite care, community referrals, and continuous patient monitoring. Operating with a dedicated workforce of 36 employees, the enterprise has successfully achieved $4 million in annual recurring revenue as of July 2025. Backed by early investments from Y Combinator, the business has raised over $21 million in total venture funding, which includes a recent $15 million Series A financing round. Craniometrix was established in 2022 by founder and chief executive officer Nikhil Patel.
Key people at Craniometrix.
Craniometrix was founded in 2021 by Nikhil Patel (Founder).
Craniometrix has raised $7.5M in total across 2 funding rounds.
Craniometrix's investors include Cathexis Ventures, Neil Sequeira, J-Ventures, Olive Tree Capital, Quiet Capital, Rebel Fund, Y Combinator.
Craniometrix has raised $7.5M across 2 funding rounds. Most recently, it raised $6.0M Seed in August 2022.
| Date | Round | Lead Investors | Other Investors | Status |
|---|---|---|---|---|
| Aug 10, 2022 | $6M Seed | — | Cathexis Ventures, Neil Sequeira, J Ventures, Olive Tree Capital, Quiet Capital, Rebel Fund, Y Combinator | Announced |
| Mar 2, 2022 | $1.5M Pre Seed | — | — | Announced |
Craniometrix is a telemedicine platform dedicated to building the world’s first one-stop-shop direct-to-consumer (D2C) care platform specifically for Alzheimer's and dementia care. It serves patients, caregivers, and healthcare providers by offering personalized, AI-driven digital diagnostics, care management tools, and 24/7 support. The platform integrates with Medicare’s GUIDE program to provide cost-efficient, comprehensive dementia care navigation that improves patient outcomes while supporting caregivers and unlocking new revenue streams for providers[1][2][4].
Founded by CEO Nikhil Patel, a Yale alumnus with a background in hedge funds and Goldman Sachs trading algorithms, Craniometrix emerged from a personal connection to Alzheimer's when a relative was diagnosed. This inspired Patel to pivot from finance to healthcare technology, focusing on early detection and care management for dementia. The company was founded around 2021-2022 and has since raised over $6 million from investors including Y Combinator, Quiet Capital, and Defy.vc. Early traction includes partnerships with Johns Hopkins MIND at Home program and achieving nearly $2 million in revenue by 2024[2][3][4][7].
Craniometrix rides the growing trend of telemedicine and AI-driven healthcare solutions, addressing the urgent need for scalable, patient-centered dementia care amid an aging population. The timing is critical as Medicare introduces new reimbursement models like GUIDE, incentivizing proactive, coordinated care. By leveraging technology to empower caregivers and reduce hospitalizations, Craniometrix influences the broader healthcare ecosystem by demonstrating how AI and digital platforms can improve chronic disease management and reduce costs[1][3][6][7].
Looking ahead, Craniometrix aims to expand its subscription offerings to include real-time doctor access and comprehensive symptom management tools, further easing the burden on caregivers and improving patient quality of life. Trends such as increased Medicare support for home-based care, advances in AI diagnostics, and growing demand for caregiver resources will shape its trajectory. As it scales, Craniometrix could redefine standards for dementia care, shifting the paradigm toward more accessible, data-driven, and compassionate support systems[3][4][7][8]. This aligns with its mission to revolutionize dementia care by making it easier, more effective, and more dignified for patients and families alike.
